Literature DB >> 2663515

Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient.

S Doi1, O Saiki, T Hara, T Sugita, K Ha-Kawa, T Tanaka, H Hara, S Negoro, H Yabuuchi, S Kishimoto.   

Abstract

A patient with ataxia telangiectasia was treated with recombinant interleukin-2 (rIL-2) and the resulting immunological effects evaluated. The patient lacked IL-2 production, and immunoglobulin synthesis was also impaired. Treatment with IL-2 selectively increased serum IgM without any significant side effects. Therapy also restored B-cell function in vitro. IgM production as well as the proliferative response to Staphylococcus aureus strain Cowan I. These results suggest that IL-2 treatment may correct both T-cell and B-cell defects.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2663515     DOI： 10.1007/bf00441517

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  22 in total

1.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

2.  Effect of recombinant IL 2 and gamma-IFN on proliferation and differentiation of human B cells.

Authors:  T Nakagawa; T Hirano; N Nakagawa; K Yoshizaki; T Kishimoto
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

3.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

4.  Soluble factor activation of human B lymphocytes.

Authors:  R J Ford; S R Mehta; D Franzini; R Montagna; L B Lachman; A L Maizel
Journal:  Nature       Date:  1981-11-19       Impact factor: 49.962

5.  Stimulation of immunoglobulin secretion in human B lymphocytes as a direct effect of high concentrations of IL 2.

Authors:  P Ralph; G Jeong; K Welte; R Mertelsmann; H Rabin; L E Henderson; L M Souza; T C Boone; R J Robb
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

6.  Antigen-induced in vitro antibody production in humans: a model for B cell activation and immunoregulation.

Authors:  D J Volkman; H C Lane; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

7.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

Authors:  M T Lotze; L W Frana; S O Sharrow; R J Robb; S A Rosenberg
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

8.  Immunologic effects of interleukin 2 in primary immunodeficiency diseases.

Authors:  N Flomenberg; K Welte; R Mertelsmann; N Kernan; N Ciobanu; S Venuta; S Feldman; G Kruger; D Kirkpatrick; B Dupont; R O'Reilly
Journal:  J Immunol       Date:  1983-06       Impact factor: 5.422

9.  Structure and expression of a cloned cDNA for human interleukin-2.

Authors:  T Taniguchi; H Matsui; T Fujita; C Takaoka; N Kashima; R Yoshimoto; J Hamuro
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962

10.  Expression of interleukin 2 receptors on activated human B cells.

Authors:  T A Waldmann; C K Goldman; R J Robb; J M Depper; W J Leonard; S O Sharrow; K F Bongiovanni; S J Korsmeyer; W C Greene
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307
View more
  2 in total

1.  Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2.

Authors:  D J Deehan; S D Heys; W Simpson; R Herriot; J Broom; O Eremin
Journal:  Clin Exp Immunol       Date:  1994-03       Impact factor: 4.330

Review 2.  Use of cytokine therapy in primary immunodeficiency.

Authors:  Sumita Roy-Ghanta; Jordan S Orange
Journal:  Clin Rev Allergy Immunol       Date:  2010-02       Impact factor: 10.817
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.